PCVX Q2 2022 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$48M

Net Income

-$49M

EPS (Diluted)

$-0.80

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$40M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$412M

Total Liabilities

$45M

Stockholders' Equity

$367M

Cash & Equivalents

$238M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$48M	-$24M	-101.8%
Net Income	-$49M	-$24M	-105.0%

Revenue Segments

Pneumococcal Conjugate Vaccine

$7.0B100%